Additionally, the localization (on tumor-infiltrating immune cells or tumor cells) and positivity threshold of PD-L1 expression for predicting ICB efficacy are still undetermined, which may affect its clinical application (1, 5, 6, 8, 15). This evidence concerns the gene CD274 and neoplasm.